Estonia as a drug testing ground: our dead are an early warning system for others

The European Union's drug agency (EMCDDA) has released a stark report: Estonia has suffered for years from the consequences of nitazenes and other potent synthetic opioids, while the rest of Europe still views them as a future threat. The Baltic states are not on the periphery of new and dangerous drug spread-they are where these substances first show signs in Europe. Information scientist and drug policy analyst Marianne Paimre examines what this means for Estonia and why Europe should take our experience seriously.

The European Union's drug agency (EMCDDA) has recently released a drug report containing an uncomfortable but crucial message for Estonia: our country has for years borne the tragic consequences of nitazenes and other potent synthetic opioids, consequences that the rest of Europe only fears.

Estonia is Europe's early warning laboratory

According to the report, the Baltics stand out clearly from the rest of Europe. While most member states treat new synthetic opioids primarily as a future threat, Estonia has for years been directly exposed to their devastating impact. The Baltic states are not a periphery where new and especially dangerous drugs arrive last-quite the opposite. It is here that these substances often first show signs across Europe.

This pattern means that what happens in Estonia is actually an early warning system for all of Europe. Our dead and our suffering are data points from which other countries can learn, if they are willing.

Why is Estonia so vulnerable?

Estonia's unique drug policy situation is no accident. The country has long-standing experience with fentanyl and other potent opioids, which have had a particularly devastating impact on the Russian-speaking community in Ida-Virumaa. Against this background, the arrival of new substances, such as nitazenes, is a continuation of already established addiction patterns.

From a drug policy perspective, the question is whether Estonia's experience is used proactively, both domestically and at the European level. Unfortunately, practice shows that international organizations often respond with delay, even when data is available.

What should Europe do?

The EMCDDA report should be a catalyst for concrete change. First, Estonia's experience should be treated not as an exceptional catastrophe, but as a precedent that may be repeated elsewhere. Second, in shaping European drug policy, greater weight should be given to the Baltic states, as they have the earliest and most deeply rooted practical experience with the spread of new substances.

Estonian deaths must not remain mere statistics. They are human lives, and their loss obliges us, and all of Europe, to act more intelligently and more quickly.